At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 19 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Exenatide on Hypothalamic Obesity
In Brief
A Phase 2 clinical trial evaluating Exenatide for Hypothalamic Obesity. Completed, enrolled 19 participants across 2 sites.
Detailed Summary
The primary aim of this study is to evaluate the effect of Exenatide on weight status (change in body mass index) of children treated for craniopharyngioma that have developed hypothalamic obesity at Children's Hospitals and Clinics of Minnesota. We hypothesize that Exenatide given to hypothalamic obese children for 6 months will reduce their body mass index significantly from baseline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypothalamic Obesity
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC.
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedFeb 2010
Primary CompletionJul 2013
Study CompletionMar 2019
TodayJul 2026
First PostedFeb 3, 2010
Enrollment StartJan 1, 2010
Primary CompletionJul 1, 2013
Study CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.4 years ago
Interventions
Exenatidedrug
5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.